{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:03:02Z","timestamp":1785229382724,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp; Metabol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/Introduction<\/jats:title>\n                    <jats:p>Imeglimin is a first\u2010in\u2010class oral antidiabetic agent that improves glycemia through dual actions on insulin secretion and sensitivity. However, real\u2010world data on its long\u2010term metabolic effects, particularly on endogenous insulin secretion, remain limited. We aimed to evaluate 12\u2010month longitudinal changes in glycemic indices, an insulin secretion index, and treatment intensity during imeglimin therapy in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included 73 Japanese patients with type 2 diabetes mellitus who continued imeglimin therapy for approximately 12 months. Hemoglobin A1c (HbA1c) and glycated albumin (GA) were assessed at baseline and follow\u2010up. Fasting plasma glucose and C\u2010peptide levels obtained between 10 and 14 months after initiation were used to calculate the fasting C\u2010peptide index (fCPI). Overall glucose\u2010lowering treatment intensity was quantified using the medication effect score (MES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HbA1c significantly decreased from 8.55%\u2009\u00b1\u20091.38% to 7.67%\u2009\u00b1\u20090.99% over 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). GA also declined from the early phase after initiation, whereas the GA\/HbA1c ratio showed only transient change without sustained differences. The fCPI increased from 1.14 [0.65\u20131.84] to 1.21 [0.79\u20132.01] (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200969,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), and an early increase was observed within 1\u20132 months. Despite frequent adjustments to background therapies, treatment intensity as assessed by MES did not change significantly.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real\u2010world setting, long\u2010term imeglimin therapy was associated with sustained glycemic improvement and early as well as sustained numerical changes in an insulin secretion index without an increase in overall treatment intensity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70263","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:02:04Z","timestamp":1783339324000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0346-1486","authenticated-orcid":false,"given":"Yohei","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Suganami","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5529-2652","authenticated-orcid":false,"given":"Masahiro","family":"Hatazaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Osaka General Medical Center  Osaka Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0763"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14285"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14613"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14642"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.211"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.371"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S38440"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S006"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-138"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1002"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K06-103"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14070"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13951"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology12050726"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.344"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2040-1124.2010.00096.x"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1742395319884096"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111752"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14001"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.193","article-title":"Imeglimin Preserves Islet \u03b2\u2010Cell Mass in Type 2 Diabetic ZDF Rats","volume":"4","author":"Hallakou\u2010Bozec S.","year":"2020","journal-title":"Endocrinology, Diabetes & Metabolism"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14410"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500097"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70449"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12159"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241651"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17657-3"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D479"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14396"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.70263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:30:02Z","timestamp":1785227402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/edm2.70263"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70263","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70263"}}